HOW CAN WE HELP YOU? Call 1-800-TRY-CHOP
Canagliflozin in Children with Type 2 Diabetes
This study is now recruiting.
The goal of this study is to investigate the efficacy and safety of Canagliflozin (which is experimental) in children and adolescents ages 10 to 18 years old with Type 2 diabetes and poor control (i.e., an HbA1c of 6.5% to 10.5%). Study drug or placebo would be taken alone or with metformin or insulin as needed. Monitoring tests include blood, urine, physical exams, vital signs, blood sugar and ketone monitoring, diabetes management counseling.
Who Do I Contact?
If you are interested in participating in the study or want to learn more please contact our study team at carchidi [at] chop.edu or 267-426-7433.
Eligibility & Criteria
IRB #:
19-016066
Official Title:
A Randomized, Multicenter, Double-Blind, Parallel-Group, Placebo-Controlled Study to Investigate the Efficacy and Safety of Canagliflozin in Children and Adolescents (≥10 to<18 years) with Type 2 Diabetes Mellitus
Study Phase:
Phase III
Eligible Age Range:
10 - 17 Years
Gender:
All
Study Categories:
Leader
